AstraZeneca and Daiichi Sankyo announced new study results for their cancer drug datopotamab deruxtecan, showing a median survival of 15.6 months in patients with EGFR-mutated non-small cell lung cancer. Agenus plans to cut annual spending by 60% to focus on a late-stage cancer immunotherapy, while Amgen is investing $1 billion to expand its manufacturing in North Carolina. The U.S. Patent and Trademark Office has withdrawn a proposed rule aimed at reducing patent thickets, and Bluebird bio is executing a reverse stock split to comply with Nasdaq rules. Merus received FDA accelerated approval for zenocutuzumab, its first approved product.
Halozyme Therapeutics has made an unsolicited bid to acquire Evotec for 11 euros per share, totaling around 2 billion euros, aiming to enhance its strategic position in the drug industry. Bluebird bio has recorded its first revenue from its gene therapy Lyfgenia for sickle cell disease, while BeiGene has rebranded as BeOne Medicines to emphasize its oncology focus and distance itself from its Chinese roots. Adaptimmune plans to lay off a third of its workforce to save $300 million and focus on its cell therapy Tecelra, while Abeona Therapeutics awaits a decision from the FDA on its gene therapy pz-cel for a rare skin condition by April 2025.
GSK is investing $800 million to expand its manufacturing site in Marietta, Pennsylvania, focusing on sterile liquid vaccines and drug substances, with operations expected by 2027 and 2028. Amgen has set a list price of $1,665 for its Eylea biosimilar, Pavblu, launching without a legal settlement, which may lead to penalties if future rulings favor Regeneron. Meanwhile, Roche has partnered with Dyno Therapeutics for gene therapy advancements, and AbbVie is collaborating with Gideon Richter on neuropsychiatric treatments. Marinus Pharmaceuticals is laying off staff after its seizure drug ganaxolone failed to meet Phase 3 study goals.
Merck & Co. has acquired Modifi Biosciences for $30 million, with potential additional payments of up to $1.3 billion based on milestones. Meanwhile, Roche reported that sales of Sarepta's gene therapy Elevidys reached approximately $156 million outside the U.S. in the first nine months of the year. Sangamo Therapeutics is on track to file for accelerated approval of its Fabry disease treatment, while MacroGenics sold rights to its breast cancer drug Margenza for $40 million, with additional milestone payments possible.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
